Zydus has been commercially manufacturing Pegylated Interferon alpha-2b under the brand name, PegiHepTM, since 2011 for the treatment of Hepatitis B and C with 1.5 lac doses being administered. PegiHepTM is not yet licensed or approved for the treatment of COVID-19.